Minerva Surgical Stock (NASDAQ:UTRS)


ForecastOwnershipChart

Previous Close

$NaN

52W Range

- - $3.49

50D Avg

$0.01

200D Avg

$0.17

Market Cap

$888.00

Avg Vol (3M)

$7.00

Beta

4.60

Div Yield

-

UTRS Company Profile


Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Show More

Industry

Medical - Healthcare Information Services

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

174

IPO Date

Oct 22, 2021

Website

UTRS Performance


Latest Earnings Call Transcripts


Q2 23Aug 07, 23 | 12:54 AM
Q1 23May 02, 23 | 10:23 PM
Q4 22Mar 21, 23 | 5:47 PM

Peer Comparison


TickerCompany
AKANAkanda Corp.
SQLSeqLL Inc.
RNAZTransCode Therapeutics, Inc.
HILSTharimmune, Inc.
DRMADermata Therapeutics, Inc.